CMMB — Chemomab Therapeutics Ltd. American Depositary Share
XNAS · Healthcare · Biotechnology
Price$2.16
Market Cap$15.8M
P/E—
52W Range$1.35 – $3.85
Next Earnings2026-11-19
About Chemomab Therapeutics Ltd. American Depositary Share
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
🤖 AI Earnings Analysis
Chemomab remains highly challenged: Q2 EPS was **-0.24**, missing by **$0.16**, with no revenue to offset burn. In biotech, the lack of a catalyst and deep losses underscore a speculative, capital-dependent story.
